- Home
- TNXP vs MTEK Comparison
TNXP vs MTEK Comparison
Compare TNXP & MTEK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TNXP
- MTEK
- Stock Information
- Founded
- TNXP 2007
- MTEK 2008
- Country
- TNXP United States
- MTEK Israel
- Employees
- TNXP N/A
- MTEK N/A
- Industry
- TNXP Biotechnology: Pharmaceutical Preparations
- MTEK
- Sector
- TNXP Health Care
- MTEK
- Exchange
- TNXP Nasdaq
- MTEK Nasdaq
- Market Cap
- TNXP 272.0M
- MTEK N/A
- IPO Year
- TNXP N/A
- MTEK 2022
- Fundamental
- Price
- TNXP $44.20
- MTEK $3.39
- Analyst Decision
- TNXP Strong Buy
- MTEK
- Analyst Count
- TNXP 2
- MTEK 0
- Target Price
- TNXP $585.00
- MTEK N/A
- AVG Volume (30 Days)
- TNXP 728.4K
- MTEK 117.5K
- Earning Date
- TNXP 08-15-2025
- MTEK 08-27-2025
- Dividend Yield
- TNXP N/A
- MTEK N/A
- EPS Growth
- TNXP N/A
- MTEK N/A
- EPS
- TNXP N/A
- MTEK N/A
- Revenue
- TNXP $10,041,000.00
- MTEK $6,078,953.00
- Revenue This Year
- TNXP $22.87
- MTEK N/A
- Revenue Next Year
- TNXP $711.66
- MTEK N/A
- P/E Ratio
- TNXP N/A
- MTEK N/A
- Revenue Growth
- TNXP N/A
- MTEK 50.80
- 52 Week Low
- TNXP $6.76
- MTEK $1.48
- 52 Week High
- TNXP $130.00
- MTEK $6.47
- Technical
- Relative Strength Index (RSI)
- TNXP 67.25
- MTEK 62.34
- Support Level
- TNXP $38.87
- MTEK $3.00
- Resistance Level
- TNXP $43.80
- MTEK $3.44
- Average True Range (ATR)
- TNXP 2.89
- MTEK 0.24
- MACD
- TNXP 0.63
- MTEK 0.01
- Stochastic Oscillator
- TNXP 77.52
- MTEK 78.72
About TNXP Tonix Pharmaceuticals Holding Corp.
Tonix Pharmaceuticals Holding Corp is a biopharmaceutical company focused on developing, licensing and commercializing therapeutics to treat and prevent human disease and alleviate suffering. Tonix's development portfolio is focused on central nervous system (CNS) disorders. The company's immunology development portfolio consists of biologics to address organ transplant rejection, autoimmunity and cancer, including TNX-1500, which is a humanized monoclonal antibody targeting CD40-ligand (CD40L or CD154) being developed for the prevention of allograft rejection and for the treatment of autoimmune diseases. Tonix also has product candidates in development in the areas of rare disease and infectious disease.